- Home
- PFX vs IGMS Comparison
PFX vs IGMS Comparison
Compare PFX & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFX
- IGMS
- Stock Information
- Founded
- PFX 2010
- IGMS 1993
- Country
- PFX United States
- IGMS United States
- Employees
- PFX N/A
- IGMS N/A
- Industry
- PFX Finance: Consumer Services
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- PFX Finance
- IGMS Health Care
- Exchange
- PFX Nasdaq
- IGMS Nasdaq
- Market Cap
- PFX 101.2M
- IGMS 82.1M
- IPO Year
- PFX N/A
- IGMS 2019
- Fundamental
- Price
- PFX $49.00
- IGMS $1.27
- Analyst Decision
- PFX
- IGMS Hold
- Analyst Count
- PFX 0
- IGMS 8
- Target Price
- PFX N/A
- IGMS $6.14
- AVG Volume (30 Days)
- PFX 1.8K
- IGMS 173.6K
- Earning Date
- PFX 05-06-2025
- IGMS 05-13-2025
- Dividend Yield
- PFX 2.92%
- IGMS N/A
- EPS Growth
- PFX N/A
- IGMS N/A
- EPS
- PFX 5.09
- IGMS N/A
- Revenue
- PFX $24,036,577.00
- IGMS $2,681,000.00
- Revenue This Year
- PFX $10.51
- IGMS $124.45
- Revenue Next Year
- PFX N/A
- IGMS $45.07
- P/E Ratio
- PFX $9.63
- IGMS N/A
- Revenue Growth
- PFX 15.02
- IGMS 27.36
- 52 Week Low
- PFX $44.32
- IGMS $0.92
- 52 Week High
- PFX $57.40
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- PFX 40.01
- IGMS 52.80
- Support Level
- PFX $48.75
- IGMS $1.13
- Resistance Level
- PFX $51.50
- IGMS $1.42
- Average True Range (ATR)
- PFX 0.78
- IGMS 0.09
- MACD
- PFX -0.00
- IGMS 0.01
- Stochastic Oscillator
- PFX 16.67
- IGMS 55.88
About PFX PhenixFIN Corporation
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.